Corteva, Inc. Q3 FY2026 earnings call

• Strategic Execution Outside Brazil: The company demonstrated strong execution against its innovation and productivity strategy in North America, EMEA, and Asia Pacific. New product volumes grew 20% globally, proving that differentiated solutions drive demand despite competitive pressures.
• Brazil Market Deterioration: Brazil remains the sole exception to the positive trend, facing severe challenges from high interest rates, currency impacts, El Niño weather, and generic pressure. Grower economics are under pressure, leading to delayed purchasing and tight channel inventory management.
• Channel Inventory Issues in Brazil: Corteva entered the year with higher-than-expected channel inventory in Brazil due to unsold products from the previous season. This overhang created significant headwinds as distributors slowed purchasing, resulting in a disproportionate impact on Corteva compared to competitors.
• Cost Discipline and Productivity: Despite revenue declines, the company maintained operating EBITDA levels flat to prior year through the first nine months. This was achieved through cost of goods sold productivity, lower SG&A spending, and increased R&D investment, absorbing approximately $230 million in pricing headwinds.
• Infrastructure Transformation: Management has initiated a critical examination of the company’s cost structure and infrastructure, engaging third-party consultants. The goal is to simplify processes, reduce complexity, and leverage technology/AI to improve efficiency, acknowledging that the inherited infrastructure is too costly.
• Capital Allocation: The Board declared Corteva’s first quarterly dividend as a stand-alone company. The company remains on track for a year-end cash position of roughly $1.5 billion, prioritizing balance sheet strength amidst market volatility.

In the third quarter of 2026, Corteva reported net sales of $1.6 billion, a 9% decline year-over-year on both a reported and organic basis. Operating EBITDA was $222 million, down 17%, with an operating margin of 14%. Year-to-date net sales totaled $5.4 billion, down 1% (organic sales down 4%), while operating EBITDA was $943 million, essentially flat with prior year levels despite significant pricing headwinds.

Regional Performance:

• North America: Sales increased by 7%, driven by a 19% volume growth in new products which offset a 12% price decline primarily due to acetochlor.
• EMEA: Sales grew 12% (14% organically), supported by a 14% volume increase from Arylex and seed treatments, with prices held flat.
• Asia Pacific: Sales grew 3% (5% organically), with volumes up 7% as the team navigated difficult weather conditions.
• Latin America: This segment acted as the primary drag, with sales declining significantly. Organic sales for Latin America were down 31%. The region accounted for approximately 45% of last year's Q3 sales, and the sharp deterioration in Brazil more than offset global growth.

• Full-Year Operating EBITDA: Updated downward from a previous estimate of ~$1.3 billion to a range of $1.1 billion to $1.125 billion. This reflects intensified pressures in Brazil, including lower expected price and volume.
• EBITDA Margin: Expected to be approximately 15% for the full year.
• Fourth Quarter Outlook: Implied fourth-quarter EBITDA is expected to be roughly half of 2025 levels on an adjusted pro forma basis, driven by the significance of Brazil to Q4 results.
• Operating EPS: Full-year operating EPS is expected to be in the range of $0.76 to $0.80 per share, representing an approximate 3% increase at the midpoint, aided by lower operating income tax expenses.
• Brazil Specifics: The company does not assume any meaningful improvement in purchasing behavior in Brazil for the remainder of the year. The estimated full-year EBITDA impact related to elevated channel inventory is approximately $100 million.
• 2027 Expectations: Management expects to grow the business in 2027, contingent on resolving inventory issues in Brazil and realizing cost-saving efficiencies. However, specific financial guidance for 2027 will be provided after reviewing full-year results and cost actions.

• Brazil Market Volatility: Significant uncertainty in the Brazilian market due to deteriorating grower economics, high interest rates, currency fluctuations, and adverse weather patterns (El Niño).
• Generic Competition: Heavy pressure from generic molecules in Brazil, particularly affecting five key products, leading to substantial price erosion.
• Channel Inventory Overhang: Elevated inventory levels in the Brazilian channel from the previous season have created a headwind, causing distributors to delay purchases and impacting Corteva disproportionately.
• Pricing Pressure: Competitive pricing pressure on older, off-patent molecules, specifically noted in North America with acetochlor and in Brazil with various late-life-cycle products.
• Operational Complexity: The inherited infrastructure and cost structure are deemed inefficient, requiring significant transformation to remain profitable, posing execution risk during the restructuring phase.

Q: Vincent Andrews asked if it is appropriate to bifurcate the business into 'everywhere else' (operating within multiyear outlook) versus Brazil (requiring reassessment of earnings power).

A: Luke Kissam confirmed this framework is fair. He noted that North America, EMEA, and Asia Pacific delivered growth despite headwinds like acetochlor pricing, staying on target for their respective outlooks. Conversely, Brazil is the major weak spot where selling season dynamics in Q3 and Q4 will continue to weigh on results, requiring significant work to fix the structural and market issues there.

Q: Kevin McCarthy asked whether the volume decline in Brazil was due to lower end-user application rates or strictly a channel destocking/inventory issue, and if this varied by region.

A: Luke Kissam clarified that on-farm applications in Brazil remain stable and Corteva is maintaining market share; the issue is strictly channel-related. Corteva had ~$250 million more revenue in the channel coming out of the previous season than others, creating an overhang. Unlike other regions where ordering is just-in-time, Brazil’s channel is burdened by this excess inventory. Jeff Rudolph added that the entire $200 million EBITDA downgrade is Brazil-driven, with half tied to reduced volume expectations from channel normalization and the other half to price erosion.

Q: Joel Jackson asked for details on the planned cost reductions and infrastructure changes to address profitability, given the engagement of third parties.

A: Luke Kissam outlined immediate actions including a hiring freeze, tightened SG&A spending, and pausing non-prioritized R&D projects to focus resources on high-impact initiatives. Longer-term, he emphasized a need to simplify processes and infrastructure, potentially moving away from certain sales models or geographies if they don't make economic sense. He stated this transformation would take 4-8 quarters and that further cost actions would be disclosed in the next earnings call.

Q: Matthew DeYoe asked if Brazil is a viable long-term market for Corteva given return on capital constraints, or if product exit/divestiture should be considered.

A: Luke Kissam acknowledged this is a core strategic question. He stated Corteva will not operate in markets where it cannot make money. However, Brazil is a critical volume hub for herbicides, and exiting could negatively impact global cost structures and competitiveness. The leadership team is methodically evaluating the right go-to-market structure (e.g., direct vs. distribution) and infrastructure needs to ensure profitability without being reactionary.

Q: Patrick Cunningham asked about the sustainability of peak revenues for off-patent actives and whether the industry is shifting toward divesting versus defending via cost reduction.

A: Luke Kissam explained that patent cliffs now result in immediate generic competition due to excess capacity in low-cost countries, shortening the profitable life cycle of molecules. To manage this, Corteva must drive costs down aggressively and use life-cycle management strategies, such as blending active ingredients with microbial or biological platforms to create differentiated packages that offer better value to growers and extend commercial viability.